Leeds, United Kingdom
adsilico Limited, founded in 2022, is spearheading the revolution in medical device development through virtual populations and in silico trials. With its slogan "Redefining medical device innovation with virtual populations and in silico trials," the company sets itself apart by offering cutting-edge solutions that aim to streamline and enhance the traditional medical device testing process.
Headquartered in the United Kingdom, adsilico Limited recently secured a substantial investment of £3.50M in an early venture capital round on 01 February 2024. The round was led by prominent investors Parkwalk Advisors and Northern Gritstone, highlighting the growing confidence in the company’s innovative approach.
The investment positions adsilico Limited for significant growth, potentially altering the landscape for medical device innovation by improving efficiency and reducing time-to-market through its technologically advanced methodologies.
